



Company Announcement no. 20/2012

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 13 November 2012

Major shareholder announcements

Pursuant to section 29 of the Danish Securities Trading Act, Veloxis Pharmaceuticals A/S (OMX: VELO) hereby makes public, that the company has received the following major shareholder announcements:

- Following completion of the rights issue on 13 November 2012, Lundbeckfond Invest A/S has increased its shareholdings and voting rights in Veloxis Pharmaceuticals A/S from 139,971,964 shares with a nominal value of DKK 0.1 each, corresponding to 30,9% of the share capital and the voting rights in Veloxis, to 708,629,942 shares with a nominal value of DKK 0.1 each, corresponding to 42,7% of the share capital and the voting rights.
- Following completing of the rights issue, Novo A/S has increased its shareholdings and voting rights in Veloxis Pharmaceuticals A/S and now owns a total of 708,629,942 shares in Veloxis with a nominal value of DKK 0.1 each, corresponding to 42,7% of the share capital and the voting rights.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino
President & CEO
Mobile: +1 917 647 9107
Email: wjp@veloxis.com

Johnny Stilou
EVP, Chief Financial Officer
Mobile: +45 21 227 227
Email: jst@veloxis.com

For further information, please visit www.veloxis.com.

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.